LOGIN  |  REGISTER
Cue Biopharma

Enhabit Home Health & Hospice Announces Date of 2023 First Quarter Earnings Call

April 20, 2023 | Last Trade: US$10.21 0.10 -0.97

DALLAS / Apr 20, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the first quarter ended March 31, 2023, on May 9, 2023, and host a webcast and conference call on May 10, 2023. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time.

  • May 10, 2023
  • 10:00 a.m. Eastern
  • Toll-free: 888-660-6150
  • International: 929-203-0843
  • Conference ID: 5248158
  • Internet website: https://investors.ehab.com

A link to the webcast of the conference call and online replay can be found on Enhabit’s investor website at the web address provided above.

About Enhabit Home Health & Hospice

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 253 home health locations and 107 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

Chimerix

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB